IF=17.5! Phase I Data of Eratrectinib Published in Experimental Hematology & Oncology

　　NTRK fusion gene is the first molecular biomarker approved for pan-tumor targeted therapy, earning it the reputation of a "diamond target". Larotrectinib, the first TRK inhibitor, obtained FDA approval in 2018 and obtained CFDA approval in 2022. Nevertheless, numerous unmet clinical needs persist among patients with NTRK fusion-positive solid tumors. On June 4, 2026, Eratrectinib, a next-generation TRK inhibitor independently developed in China, was granted marketing authorization. Recently, results from its Phase I clinical trial were published in Experimental Hematology & Oncology.

　　Literature Overview

　　Title: Safety, Efficacy and Pharmacokinetics of Eratrectinib (VC004) in NTRK Fusion-Positive Solid Tumors: Phase I Clinical Results from a Phase 1/2 Study

　　Journal: Experimental Hematology & Oncology

　　Publication Date: June 26, 2026

　　Impact Factor (IF): 17.5

　　Journal Ranking: Top Journal in Q1 of the Medicine Major Category in the 2026 New Release Journal Partition, JCR Q1

　　Key Study Outcome: Based on safety, pharmacokinetic (PK) and efficacy data, the Recommended Phase II Dose (RP2D) was finalized as 50 mg twice daily.

　　Professor Shi Yuankai, Principal Investigator of Eratrectinib (VC004) from Aerospace Center Hospital / National Cancer Center, Chinese Academy of Medical Sciences, stated: "The core tenet of precision medicine lies in delivering tangible clinical therapeutic value to patients with severe and refractory malignancies. The publication of our Phase I clinical findings in Experimental Hematology & Oncology lays a solid foundation for subsequent clinical research of Eratrectinib. We believe that as clinical investigations progress further, the efficacy and safety profile of Eratrectinib will be presented in a more comprehensive and objective manner."

　　Dr. Gong Yanchun, Co-founder, Chairman and CEO of Vcare PharmaTech, commented: "As the first innovative drug developed by Vcare PharmaTech to receive marketing approval, Eratrectinib delivers pivotal clinical therapeutic benefits to patients with NTRK fusion-positive solid tumors. We are greatly encouraged that the Phase I clinical data of this agent has been formally published in Experimental Hematology & Oncology, an authoritative international journal covering hematology and oncology. This publication not only serves as high recognition of the high quality and rigorous design of our clinical trial, but also further demonstrates our robust R&D capabilities."

　　At present, Eratrectinib has successfully completed pivotal Phase II clinical trials and obtained marketing approval. Its Phase III clinical trial enrolling a broader patient population is actively recruiting participants. Phase II data demonstrated that patients with more than 6 months of follow-up achieved an Objective Response Rate (ORR) of 89.7% and a median Overall Survival (mOS) of 40.7 months, with a treatment discontinuation rate of only 2.2% due to Adverse Drug Reactions (ADRs), reflecting outstanding efficacy and favorable safety.

　　With continuous advancement of follow-up clinical studies and accumulation of real-world evidence, the long-term efficacy and safety of Eratrectinib will be more fully validated, and its indication scope is expected to expand further. This will provide more robust treatment options and new clinical alternatives for domestic patients diagnosed with NTRK fusion-positive solid tumors.